Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 1051 AL 1065

[Pathobiology of Alzheimer's disease and biomarker development]

Arai H, Okamura N, Waragai M, Furukawa K, Yanai K, Kudo Y.

Nihon Yakurigaku Zasshi. 2010 Jan;135(1):3-7. doi: 10.1254/fpj.135.3.

NEP-like endopeptidases and Alzheimer's disease [corrected]

Marr RA, Spencer BJ.

Curr Alzheimer Res. 2010 May;7(3):223-9. doi: 10.2174/156720510791050849.

Imaging as a strategy for premortem diagnosis and staging of tauopathies

Kim S, Jensen JR, Cisek K, Funk KE, Naphade S, Schafer K, Kuret J.

Curr Alzheimer Res. 2010 May;7(3):230-4. doi: 10.2174/156720510791050894.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16.

Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation

Habek M, Hajnsek S, Zarković K, Chudy D, Mubrin Z.

Can J Neurol Sci. 2010 Jan;37(1):118-20.

Microglia activation and anti-inflammatory regulation in Alzheimer's disease

Lue LF, Kuo YM, Beach T, Walker DG.

Mol Neurobiol. 2010 Jun;41(2-3):115-28. doi: 10.1007/s12035-010-8106-8. Epub 2010 Mar 3.

[Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease]

Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pampliega-Pérez A, Montoya-Gutiérrez J, Leiva-Santana C.

Rev Neurol. 2010 Feb 16-28;50(4):193-200.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131.

Impact of the CD40-CD40L dyad in Alzheimer's disease

Giunta B, Rezai-Zadeh K, Tan J.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.

Alzheimer's disease and retinal neurodegeneration

Guo L, Duggan J, Cordeiro MF.

Curr Alzheimer Res. 2010 Feb;7(1):3-14. doi: 10.2174/156720510790274491.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

[Diagnosis of Alzheimer's disease]

Derouesné C.

Psychol Neuropsychiatr Vieil. 2010 Mar;8(1):5-6. doi: 10.1684/pnv.2010.0202.

[What use of biological markers for the diagnosis of Alzheimer's disease and associated disorders?]

Krolak-Salmon P.

Psychol Neuropsychiatr Vieil. 2010 Mar;8(1):25-31. doi: 10.1684/pnv.2009.0189.

[Importance of molecular diagnostics in Alzheimer dementia. A case report]

Honneth J, Nehen HG, Haseke J.

Z Gerontol Geriatr. 2010 Jun;43(3):177-9. doi: 10.1007/s00391-010-0101-1. Epub 2010 Apr 1.

Cerebrospinal fluid biomarkers of Alzheimer's disease

Fagan AM, Holtzman DM.

Biomark Med. 2010 Feb;4(1):51-63. doi: 10.2217/BMM.09.83.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias